US · Healthcare · Biotechnology
EPS came in at -0.28 against a street estimate of -0.23 — a miss of 21.7%.
Analysts rate Annexon Inc a buy (8 buy, 2 hold, 0 sell out of 10) with an average price target of $15.43.
| Fund | Stake |
|---|---|
| FMR Inc | 10.30% |
| BlackRock Inc | 7.14% |
| Redmile Group, LLC | 6.26% |
| State Street Corp | 5.18% |
| Bvf Inc | 4.59% |
| Woodline Partners LP | 3.65% |
| Vanguard Capital Management, LLC | 3.62% |
| Mak Capital One LLC | 3.09% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ANNEXON, INC. — FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Short-Term Investments: $209.2 million as of June 3 | 2026-08-12 |
| Results announced · Q3 2026 ANNEXON, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $209.2 million in cash, cash equivalents and short-term investme | 2026-08-12 |
| Board / officer change · Q3 2026 ANNEXON, INC. – 8-K FILING SUMMARY Date: August 10, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Board Leadership Change: Muneer Satter resigned from t | 2026-08-10 |
| Company announcement · Q3 2026 ANNEXON, INC. - 8-K FILING SUMMARY (August 6, 2026) HEADLINE NUMBERS • Company: Annexon, Inc. (Nasdaq: ANNX) • Filing Date: August 6, 2026 • Headqua | 2026-08-06 |
| Material agreement · Q3 2026 ANNEXON, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company secured a $200.0 million Loan and Security Agreement with Oxford Finance LLC effective July 3 | 2026-07-30 |
| Quarterly report · Q1 2026 ANNEXON, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $175.2 million in cash and cash equivalents plus $49.8 million in short-term | 2026-05-07 |
| Proxy statement · Q2 2026 ANNEXON, INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Douglas Love (President and CEO) total compensation: Not specified in this document excerpt | 2026-04-27 |
| Annual report FY2025 ANNEXON, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company Type: Clinical-stage biopharmaceutical company, no FDA-approved product | 2026-03-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Annexon Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.